Literature DB >> 29359470

Shining LIGHT on the metabolic role of the cytokine TNFSF14 and the implications on hepatic IL-6 production.

Bernadette M Saunders1,2, Caroline Rudnicka3, Aleksandra Filipovska4,5, Stefan Davies4, Natalie Ward6,7, Jana Hricova8, Markus P Schlaich8,9, Vance B Matthews8.   

Abstract

The cytokine Tumor Necrosis Factor Superfamily member 14, TNFSF14 (or LIGHT), is a controversial player in numerous diseases. We investigated the role of endogenously expressed TNFSF14 in diet-induced obesity in vivo. Firstly, we studied the effects of Tnfsf14 ablation on the development of obesity, glucose intolerance, insulin resistance, steatosis, tissue inflammation, and mitochondrial respiration in the liver. Secondly, we examined the role of TNFSF14 expression in hematopoietic cells on obesity and insulin sensitivity. Male Tnfsf14 knockout (KO) and wild type mice were fed chow or high fat diet (HFD) for 12 weeks and were assessed for weight gain, glucose intolerance, insulin resistance, hepatosteatosis, mitochondrial dysfunction, and cytokine expression. Wild-type mice were also reconstituted with bone marrow cells from Tnfsf14 knockout mice and were fed chow or HFD for 12 weeks. These mice were examined for weight gain and insulin resistance. HFD fed mice had elevated circulating levels of serum TNFSF14. Liver and white adipose tissue are potential sources of this elevated TNFSF14. Tnfsf14 deficient mice displayed increased obesity, glucose intolerance, insulin resistance, hepatosteatosis, and mitochondrial dysfunction compared to control mice on a HFD. Hepatic cytokine profiling pointed to a potential novel role of decreased IL-6 in the metabolic disturbances in obesogenic Tnfsf14 knockout mice. Bone marrow cells from Tnfsf14 deficient mice appeared to promote diet-induced obesity, insulin resistance and reduced FGF21 levels in white adipose tissue and liver. Our novel data suggest that Tnfsf14 ablation exacerbates parameters of the metabolic syndrome under high fat feeding conditions and provides evidence to support the development of TNFSF14 agonists as potential therapeutics in diet-induced obesity.
© 2017 Australasian Society for Immunology Inc.

Entities:  

Keywords:  IL‐6; TNFSF14; diabetes; insulin resistance; liver; obesity

Mesh:

Substances:

Year:  2017        PMID: 29359470     DOI: 10.1111/imcb.1002

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN: 0818-9641            Impact factor:   5.126


  5 in total

1.  Realigning the LIGHT signaling network to control dysregulated inflammation.

Authors:  Carl F Ware; Michael Croft; Garry A Neil
Journal:  J Exp Med       Date:  2022-05-23       Impact factor: 17.579

2.  Genetic inactivation of the LIGHT (TNFSF14) cytokine in mice restores glucose homeostasis and diminishes hepatic steatosis.

Authors:  Andrea Herrero-Cervera; Ángela Vinué; Deborah J Burks; Herminia González-Navarro
Journal:  Diabetologia       Date:  2019-08-06       Impact factor: 10.122

3.  The Influence of Hypertensive Therapies on Circulating Factors: Clinical Implications for SCFAs, FGF21, TNFSF14 and TNF-α.

Authors:  Aaron L Magno; Lakshini Y Herat; Márcio G Kiuchi; Markus P Schlaich; Natalie C Ward; Vance B Matthews
Journal:  J Clin Med       Date:  2020-08-26       Impact factor: 4.241

4.  Reduced mitochondrial translation prevents diet-induced metabolic dysfunction but not inflammation.

Authors:  Kara L Perks; Nicola Ferreira; Judith A Ermer; Danielle L Rudler; Tara R Richman; Giulia Rossetti; Vance B Matthews; Natalie C Ward; Oliver Rackham; Aleksandra Filipovska
Journal:  Aging (Albany NY)       Date:  2020-10-06       Impact factor: 5.682

5.  Metabolic activation and colitis pathogenesis is prevented by lymphotoxin β receptor expression in neutrophils.

Authors:  Thomas Riffelmacher; Daniel A Giles; Sonja Zahner; Martina Dicker; Alexander Y Andreyev; Sara McArdle; Tamara Perez-Jeldres; Esmé van der Gracht; Mallory Paynich Murray; Nadine Hartmann; Alexei V Tumanov; Mitchell Kronenberg
Journal:  Mucosal Immunol       Date:  2021-02-10       Impact factor: 7.313

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.